Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

GHRP-6 10 mg
GHRP-6 10 mg

GHRP-6 10 mg

GHRP-6 10 mg from the Endogenic line – lyophilisate in a vial, a historical prototype of the class of growth hormone releasing peptides (GHRP) and a synthetic ghrelin mimetic. It stimulates the GHS-R1a ghrelin receptor, leading to pulsatile GH release and somatostatin suppression; the strongest orexigenic GHRP – a model ligand for studying ghrelin as an appetite regulator. Research Use Only

19,99 €
With code BLACK: 15,99 € Lowest price in the 30 days before the discount: 19,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
View the laboratory analysis report Peptide Calculator

GHRP-6 10 mg - growth hormone releasing hexapeptide, RUO research reagent

  • GHRP-6: synthetic hexapeptide from the GHRP class.
  • 10 mg lyophilisate in a vial.
  • Research Use Only reagent, not a medicinal product.

Product status information

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

Regulatory framework – growth hormone secretagogue from the Endogenic line

GHRP-6 (Growth Hormone Releasing Peptide 6) from the line Endogenic is a research reagent in the form of a lyophilized 10 mg in a vial, belonging to the class of growth hormone releasing peptides (GHRP) – synthetic ghrelin mimetics acting on the growth hormone secretion receptor type 1a (GHS-R1a). GHRP-6 is not registered as a medicinal product in any jurisdiction.

The molecule belongs to the class of growth hormone secretagogues, which WADA lists in Section S2 of the Prohibited List. (peptide hormones, growth factors and mimetics) – permanently prohibited substance, both in and out of competition. Communication suggesting use in humans to increase growth hormone, IGF-1 levels, stimulate appetite, accelerate regeneration or change body composition is contrary to the Research Use Only framework and is unacceptable.

Introduction

Line Endogenic Pro-Body groups reagents that work not by administering an exogenous hormone, but by stimulation own body’s secretory mechanisms in research models. GHRP-6 is one of the historically most important compounds of this class – a hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, with which Cyril Bowers’ team initiated the entire pharmacology of growth hormone secretagogues in 1984 (Bowers et al. 1984).

It was on GHRP-6 that it was discovered that there was a pathway separate from GHRH to stimulate GH release – a discovery that, years before the identification of ghrelin itself, pointed to the existence of an unknown receptor and an unknown endogenous ligand.

GHRP-6 is the founding compound in the GHRP family and also the most “raw” in terms of profile. Unlike the later, selective one Ipamorelin, GHRP-6 stimulates the release of growth hormone, but in parallel triggers a strong orexigenic signal – it is the strongest appetite stimulator among the classic GH-releasing peptides – and mildly modifies the cortisol-prolactin axis.

This “full” ghrelin profile makes it, on the one hand, less of a “pure” tool for studying the GH axis itself, and, on the other hand, a model ligand for studying ghrelin as a whole, including its appetite regulation arm. This reagent is supplied as 10 mg lyophilisate in a vial, for reconstitution with bacteriostatic water in laboratory conditions.

The freeze-dried form ensures stability of the peptide before dissolution and allows researchers to prepare working concentrations tailored to the experimental design. Purity verified by HPLC ≥98%, identity confirmed by Q-TOF mass spectrometry, COA available for each batch. The single-component line remains available alongside related secretagogues: GHRP-2 — stronger GH with a lower appetite signal — as a reference point for comparative research on selectivity within the GHRP class. The broader catalog of this group includes growth hormone-increasing peptides — GHRP secretagogues and GHRH analogues combined in one category.

General description - GH/ghrelin axis and pulsatile secretion of growth hormone

To understand where GHRP-6 resides in physiology, you need to see that the pituitary gland receives the “secrete growth hormone” signal through more than one channel. The somatotropic cell of the anterior pituitary has at least two separate receptors on its surface that stimulate GH release: GHRH receptor (growth hormone releasing hormone) and growth hormone secretion receptor type 1a (GHS-R1a), i.e. ghrelin receptor.

These are two different proteins, two different intracellular cascades and two different physiological signals – which converge on the same end result, the release of GH from secretory granules. GHRP-6 acts on the second of these channels – the ghrelin arm.

Growth hormone is not secreted in a flat, steady stream – the pituitary gland releases GH impulses, in pulses of a specific amplitude and frequency, regulated by a pair of opposing signals from the hypothalamus. GHRH tells the pituitary “secrete”, somatostatin says “hold”. There is a third player on top of this system – ghrelin and its receptor GHS-R1a – which acts as a separate, complementary switch for GH release and, importantly for GHRP-6, suppresses somatostatin (takes off the brake) and enhances its own GHRH effect.

The pharmacology of GH-releasing peptides arises precisely from the question: what happens when we stimulate this third channel separately? The pulsatile nature of GH secretion is the main physiological detail here.

Unlike exogenous, recombinant growth hormone, which floods the circulation with a flat, nonphysiological concentration, secretagogues stimulate own pituitary to release GH in a way that preserves the pulsatile signal architecture – involving the somatostatin feedback loop. This “endogenous, pulsatile” release pattern is the subject of research into the physiology of the GH/IGF-1 axis. The pharmacology of growth hormone secretagogues includes two large classes of tools:

  • GHRH analogues — imitate the endogenous GH-releasing hormone, stimulate the GHRH receptor, increase the pulse amplitude (CJC-1295 with DAC, sermorelin, tesamorelin)
  • GH-releasing peptides (GHRP) and ghrelin mimetics — stimulate the GHS-R1a ghrelin receptor, increase the pulse rate and suppress somatostatin (GHRP-6, GHRP-2, hexarelin, Ipamorelin)

GHRP-6 is historical prototype second class – the peptide on which this class is defined. It is also its most orexigenic representative: among the classic GHRPs, GHRP-6 stimulates appetite most strongly by activating ghrelin in the hypothalamus, which makes it a model tool not only for studying the GH axis, but also for studying ghrelin as an appetite regulator.

What is GHRP-6?

Chemically, GHRP-6 is a synthetic hexapeptide with a C-terminal amide, composed of natural and unnatural residues (D-amino acids increasing resistance to proteolysis).

  • Common name: GHRP-6, Growth Hormone Releasing Peptide 6
  • Chemical name/sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (hexapeptide, C-terminal amide)
  • Synonyms: GHRP6, growth hormone releasing hexapeptide, SKF-110679 (historical designation)
  • CAS number: 87616-84-0
  • Molecular formula: C₄₆H₅₆N₁₂O₆
  • Molar mass: 873.01 g/mol
  • Chemical class: hexapeptide, growth hormone releasing peptide (GHRP); agonist of the growth hormone secretion receptor GHS-R1a – a synthetic ghrelin mimetic
  • Delivered form: lyophilisate 10 mg in a vial, for reconstitution with bacteriostatic water; pharmaceutical grade ≥98% HPLC

Origin: GHRP-6 is derived from Cyril Bowers’ work on enkephalin analogues for growth hormone releasing activity. Groundbreaking characterization was published in 1984 (Bowers et al.), demonstrating in vitro and in vivo that this synthetic hexapeptide stimulates GH release through a pathway distinct from GHRH. This observation initiated the search for the intermediary receptor – cloned in 1996 as GHS-R1a – and its endogenous ligand, which turned out to be ghrelin, identified only in 1999 by Kojima’s team.

GHRP-6 therefore functioned as a pharmacological tool that anticipates the discovery of one’s own physiological system: first the synthetic ligand and its effect were known, and only then the receptor and hormone it imitates. Compound has remained an important research tool in the endocrinology of the somatotropic axis and in the pharmacology of ghrelin.

Mechanism of action at the molecular level

GHRP-6 works by stimulating the ghrelin receptor GHS-R1a on somatotropic cells in the pituitary and hypothalamus. Unlike GHRH analogues, the compound does not stimulate the GHRH receptor – it activates a separate pathway that in physiology is responsible for the ghrelin arm in regulating the release of growth hormone. Below are the best documented mechanisms observed in preclinical models. Pharmacological profile observed in preclinical models:

  1. GHS-R1a ghrelin receptor agonism → pulsatile GH release — GHS-R1a is a Gq protein-coupled receptor. Stimulation of GHRP-6 activates phospholipase C, increases intracellular calcium and leads to the release of growth hormone from the secretory granules of the somatotropic cell – by a route separate from the Gs/cAMP cascade characteristic of GHRH. Effect: stimulation of the frequency and pulsatility of GH release (Bowers et al. 1984; Smith et al. 1997)
  2. Strong appetite stimulation – activation of ghrelin in the hypothalamus — this is the most distinguishing feature of GHRP-6 within the class. As a ghrelin mimetic, GHRP-6 stimulates GHS-R1a receptors in the arcuate nucleus of the hypothalamus, activating orexigenic neurons (NPY/AgRP). In rodent models, this translates into a strong hunger signal – GHRP-6 is the strongest orexigenic representative of the classic GHRPs, which makes it a model ligand for studying ghrelin as an appetite regulator, regardless of its GH-secretagogic profile
  3. Modulation of cortisol and prolactin — by stimulating the ghrelin axis, GHRP-6 causes a mild increase in cortisol and prolactin and a limited effect on ACTH release. This behavior distinguishes it from selective Ipamorelin, which in preclinical models stimulated GH without a significant release of stress hormones. GHRP-6 lies on the “older”, less selective end of the GHRP spectrum
  4. Somatostatin suppression — the ghrelin arm not only directly stimulates the release of GH, but also takes off the brake in the form of somatostatin (a hormone that inhibits GH secretion). By doing so, GHRP-6 also enhances the somatotroph cell response to endogenous GHRH – a mechanism that underlies the synergy observed when GHRP combines with a GHRH analogue in research models
  5. Potential cytoprotective effect — regardless of the GH axis, research on GHRP-6 indicates a cytoprotective profile, including a cardioprotective direction: in models of myocardial ischemia/reperfusion, the effect of GHRP-6 on reducing the area of ​​damage and markers of cardiomyocyte survival was studied, partly independently of GH stimulation (direction of research on CD36 and GHS-R receptors in cardiac tissue; Berlanga-Acosta et al. 2017)

Pharmacokinetic profile (based on preclinical models and historical data):

  • Half-life in plasma: short, in the order of several dozen minutes – peptide partially stabilized by D-amino acid residues (D-Trp, D-Phe) against proteolysis, but still with limited plasma stability
  • Penetration of the blood-brain barrier: limited; the orexigenic effect takes place mainly through GHS-R1a receptors available for circulation (arcuate nucleus of the hypothalamus)
  • Metabolism: enzymatic hydrolysis of peptide bonds; degradation products are shorter fragments and free amino acids
  • PK profile in humans: insufficiently characterized; available data come from limited, early studies

GHRP-6 vs selective Ipamorelin – position within the GHRP class: In the landscape of growth hormone releasing peptides, GHRP-6 and Ipamorelin represent two opposite ends of the selectivity spectrum:

  • GHRP-6 — historical prototype, “full” ghrelin mimetic: stimulates GH, but strongly stimulates appetite (the strongest orexigenic GHRP) and gently increases cortisol and prolactin. This is a complete profile of ghrelin activation, including its craving arm and stress axis
  • Ipamorelin — later, selective pentapeptide: stimulates GH via GHS-R1a with virtually no increase in cortisol, prolactin and without a strong appetite signal (Raun et al. 1998). “Clean” GH secretagogue
  • Methodological conclusion: the choice of peptide in the research model depends on the question. When the subject of the study is the GH axis itself without disturbances of the stress axis, Ipamorelin is preferred. When the subject is ghrelin as a whole (GH + appetite + cortisol axis) – the model ligand is GHRP-6

Applications in scientific research

GHRP-6 as an RUO reagent is used where the subject of research is ghrelin arm in the regulation of the somatotropic axis and ghrelin as an appetite regulator. In vivo models (rat, mouse, pig as a model species for GH physiology) and in vitro models (isolated somatotropic pituitary cells, cell lines expressing the GHS-R1a receptor) are conducted on the mechanism, kinetics and selectivity. Specific research directions include:

  • Pharmacology of the GHS-R1a ghrelin receptor — GHRP-6 as a prototype synthetic agonist; Gq/phospholipase C cascade studies, concentration-response curves, binding characteristics in cell preparations
  • Pulsatility and architecture of GH secretion — how stimulation of the ghrelin arm modifies the amplitude and frequency of growth hormone pulses; comparison of the release pattern with stimulation with a GHRH analogue and with the administration of recombinant GH
  • Ghrelin as an appetite regulator — GHRP-6 as a model orexigenic ligand; studies of the activation of NPY/AgRP neurons in the arcuate nucleus of the hypothalamus, regulation of energy balance and hunger signaling
  • Receptor selectivity within GHRP — comparative studies on the selectivity of GHRP-6 vs GHRP-2 vs Ipamorelin towards the GH axis and the cortisol/prolactin/ACTH axis in cell preparations and in vivo models
  • Somatostatin suppression and synergy with GHRH — the role of GHRP-6 in abolishing somatostatin inhibition and potentiating the GHRH response; studies of the feedback loop regulating the GH pulse
  • Cytoprotection and cardioprotective direction — studies on the effect of GHRP-6 on cardiomyocyte survival markers in ischemia/reperfusion models, partially independent of the GH axis (GHS-R and CD36 receptors in cardiac tissue)

Regulatory status

GHRP-6 belongs to the class growth hormone secretagogues, which WADA lists in section S2 of the prohibited list — “peptide hormones, growth factors, related substances and mimetics”. This section includes GH-releasing peptides and ghrelin mimetics (GHRP-6, GHRP-2, hexarelin, Ipamorelin) and GHRH analogues. The substance is there permanently prohibited — both in and out of competition. There is an absolute ban for registered athletes (ADAMS). GHRP-6 is not registered as a medicinal product in the EU, USA or anywhere in the world. Registered athletes must check the current list of prohibited substances before making any decision regarding use.

Summary

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) from the Endogenic line historical prototype of the class of growth hormone-releasing peptides — hexapeptide, with which the Bowers team initiated the pharmacology of GH secretagogues in 1984, years before the identification of the GHS-R1a receptor (1996) and ghrelin itself (1999). Mechanistically, GHRP-6 is a synthetic ghrelin mimetic: it stimulates the GHS-R1a receptor (Gq cascade/phospholipase C) on pituitary somatotropic cells, leading to pulsatile GH release and somatostatin suppression.

The distinguishing feature is the strongest orexigenic profile in its class — strong stimulation of appetite by activating ghrelin in the hypothalamus — and a mild increase in cortisol and prolactin, which distinguishes it from selective Ipamorelin. The cytoprotective/cardioprotective direction is also being investigated, partially independent of the GH axis. Lyophilized form 10 mg in a vial, reconstitution with bacteriostatic water, HPLC purity ≥98%, MS Q-TOF, COA for each batch. Regulatory Status – Research Use Only; lack of registration as a medicine; WADA: Section S2, Permanent Prohibited Substance.

Bibliography

  1. Bowers CY, Momany FA, ​​Reynolds GA, Hong A (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. PubMed
  2. Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, et al. (1997). Peptidomimetic regulation of growth hormone secretion. PubMed
  3. Sigalos JT, Pastuszak AW (2018). The Safety and Efficacy of Growth Hormone Secretagogues. PubMed
  4. Berlanga-Acosta J, Abreu-Cruz A, Herrera DGB, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, et al. (2017). Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. PubMed
  5. Cordido F, Peñalva A, Dieguez C, Casanueva FF (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6. PubMed